Welcome to our dedicated page for Bionano Genomics news (Ticker: BNGO), a resource for investors and traders seeking the latest updates and insights on Bionano Genomics stock.
Bionano Genomics, Inc. reports developments in genome analysis solutions built around optical genome mapping (OGM), diagnostic services, software and nucleic acid extraction technologies. Company updates commonly address OGM applications in cytogenetics, rare disease research, hematologic malignancies, reproductive disorders and other genomic-analysis workflows, including published studies comparing OGM with karyotyping, FISH, chromosomal microarrays, next-generation sequencing and long-read sequencing.
Recurring news also covers financial results, revenue outlooks, scientific-meeting presentations, Bionano Symposium activity, use of VIA™ software, the Ionic® system and Bionano Laboratories diagnostic testing services. Governance updates include board and executive leadership changes at the Nasdaq-listed life sciences instrumentation company.
Bionano Genomics (Nasdaq: BNGO) announced plans for an underwritten public offering of its common stock, subject to market conditions. The offering aims to raise capital, though no details regarding size or terms are confirmed. Bionano intends to grant underwriters a 30-day option for an additional 15% of shares for over-allotments. Oppenheimer & Co. Inc. leads the offering, with BTIG, Ladenburg Thalmann, and Maxim Group as co-managers. The offering is registered under a previously filed shelf registration statement, effective since January 19, 2021.
Bionano Genomics announced the publication of a study comparing its Saphyr system with traditional cytogenomics methods for analyzing Myelodysplastic Syndromes (MDS). The study showed that optical genome mapping (OGM) detected all actionable variants and additional relevant aberrations missed by standard methodologies, enhancing clinical decision-making. Saphyr reduces the diagnostic process from weeks to just 4 days, potentially accelerating patient treatment. With OGM's high-throughput capabilities, it may streamline chromosomal analysis for MDS and other cancers.
Bionano Genomics (NASDAQ: BNGO) announced findings from the COVID-19 Host Genome Structural Variant Consortium, highlighting the Saphyr system's effectiveness in identifying structural variants (SVs) in severe COVID-19 patients. Key findings indicate that SVs affecting immunity and viral replication pathways are linked to disease severity, particularly in the interferon response pathway. The consortium aims to analyze 1,000 genomes to enhance understanding of COVID-19 susceptibility, with significant collaborations from renowned institutions worldwide.
Bionano Genomics (BNGO) highlighted groundbreaking advancements in optical genome mapping (OGM) with its Saphyr system during a recent symposium. Notable achievements include the ability to assess large genomic repeat expansions previously deemed unmeasurable. Clinical validations presented suggest that Saphyr enhances diagnostic accuracy, exemplified by a 25% increase in diagnostic yield for undiagnosed genetic diseases. The University of Iowa and KU Leuven also developed cost-effective assays for Facioscapulohumeral Muscular Dystrophy (FSHD) testing, advancing clinical diagnostics in pediatric genetic disorders.
Bionano Genomics (BNGO) announced positive preliminary findings on its Saphyr system, presented at the Next-Generation Cytogenomics Symposium. The system demonstrated superior performance over the Oncoscan array for detecting structural and copy number variations in solid tumors. Six studies highlighted Saphyr's capability to unveil complex genomic changes in various cancers, including brain and breast cancers, revealing new therapeutic targets. The studies showed that Saphyr achieved 100% concordance with existing testing methods while offering faster, cost-effective solutions for clinical applications.
Bionano Genomics (Nasdaq: BNGO) announced its compliance with Nasdaq's minimum bid price requirement. The company received a notification confirming that its common stock closing bid price has been at $1.00 or greater for the last 10 consecutive business days, from December 29, 2020, to January 12, 2021. This achievement fulfills the Listing Rule 5550(a)(2) criteria, and the matter is now considered closed.
Bionano Genomics (BNGO) announced successful results from Saphyr users at the Next-Generation Cytogenomics Symposium, demonstrating its efficacy in analyzing hematological malignancies. Saphyr identifies actionable genetic variants better than traditional cytogenetic methods, such as karyotyping and FISH, while offering faster results at a lower cost. KU Leuven Hospitals is adopting the Saphyr-based assay for routine Acute Lymphoblastic Leukemia diagnostics, showcasing its potential to streamline clinical workflows and improve diagnostic accuracy.
Bionano Genomics, Inc. (BNGO) has successfully closed its underwritten public offering of 33,368,851 shares at $3.05 per share, raising approximately $101.8 million in gross proceeds. This offering includes the full exercise of the underwriters' option to purchase 4,352,458 additional shares. The shares were offered under a previously filed shelf registration statement and are designed to support Bionano's genome analysis services and products.
Bionano Genomics presented findings at the Next-Generation Cytogenomics Symposium, showcasing the Saphyr system's effectiveness in genetic testing. Notable achievements include a 100% concordance in prenatal testing between Saphyr and standard methods like karyotyping, leading to quicker and cost-effective results. Studies across the US, Europe, and China demonstrated Saphyr's reproducibility and ability to resolve rare genetic diseases. Experts from various institutions highlighted Saphyr's advantages in uncovering actionable insights, thereby enhancing diagnostic capabilities in genetic disorders.
Bionano Genomics (Nasdaq: BNGO) announced the publication of findings from the COVID-19 Host Genome Structural Variant Consortium. The study utilized the Saphyr System to identify significant structural variants (SVs) linked to immune responses and disease severity in COVID-19 patients. Analysis of 37 ICU patients revealed that 12 died, while 25 recovered. Notably, a duplication of the STK26 gene was associated with severe illness, suggesting its potential as a prognostic biomarker. The findings highlight Saphyr’s capability in revealing critical genetic insights overlooked by traditional methods.